The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could apply to other biologics as well. “When we looked at the ...

That’s a drop in the ocean compared to the CHF 1.5 billion and CHF 910 million in Herceptin and Perjeta sales, respectively, in the same period, but with Phesgo Roche is looking to the future.

However, Roche faced a CHF 1bn sales decline from the loss of exclusivity on older products, including cancer therapies Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan (rituximab).

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Blockbuster cancer biologics Avastin, Rituxan, and Herceptin are seeing strong headwinds from biosimilars. However, Roche's biologics focus (more than 80% of pharmaceutical sales) provides some ...